Pen Needles Market (By Product: Standard Pen Needles, Safety Pen Needles; By Needle Length: 4 mm, 5 mm, 6 mm, 8 mm, 10 mm, 12 mm; By Therapy: Insulin, Glucagon-like-Peptide-1 (GLP-1), Growth Hormone) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2024-2033
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Pen Needles Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Pen Needles Market Revenue and Volume, by Product, 2024-2033
8.1.1 Standard Pen Needles
8.1.1.1. Market Revenue and Volume Forecast (2021-2033)
8.1.2. Safety Pen Needles
8.1.2.1. Market Revenue and Volume Forecast (2021-2033)
9.1. Pen Needles Market Revenue and Volume, by Needle Length, 2024-2033
9.1.1. 4 mm
9.1.1.1. Market Revenue and Volume Forecast (2021-2033)
9.1.2. 5 mm
9.1.2.1. Market Revenue and Volume Forecast (2021-2033)
9.1.3. 6 mm
9.1.3.1. Market Revenue and Volume Forecast (2021-2033)
9.1.4. 8 mm
9.1.4.1. Market Revenue and Volume Forecast (2021-2033)
9.1.5. 10 mm
9.1.5.1. Market Revenue and Volume Forecast (2021-2033)
9.1.6. 12 mm
9.1.6.1. Market Revenue and Volume Forecast (2021-2033)
10.1. Pen Needles Market Revenue and Volume, by Therapy, 2024-2033
10.1.1. Insulin
10.1.1.1. Market Revenue and Volume Forecast (2021-2033)
10.1.2. Glucagon-like-Peptide-1 (GLP-1)
10.1.2.1. Market Revenue and Volume Forecast (2021-2033)
10.1.3. Growth Hormone
10.1.3.1. Market Revenue and Volume Forecast (2021-2033)
11.1. North America
11.1.1. Market Revenue and Volume Forecast, by Product (2021-2033)
11.1.2. Market Revenue and Volume Forecast, by Needle Length (2021-2033)
11.1.3. Market Revenue and Volume Forecast, by Therapy (2021-2033)
11.1.4. U.S.
11.1.4.1. Market Revenue and Volume Forecast, by Product (2021-2033)
11.1.4.2. Market Revenue and Volume Forecast, by Needle Length (2021-2033)
11.1.4.3. Market Revenue and Volume Forecast, by Therapy (2021-2033)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Volume Forecast, by Product (2021-2033)
11.1.5.2. Market Revenue and Volume Forecast, by Needle Length (2021-2033)
11.1.5.3. Market Revenue and Volume Forecast, by Therapy (2021-2033)
11.2. Europe
11.2.1. Market Revenue and Volume Forecast, by Product (2021-2033)
11.2.2. Market Revenue and Volume Forecast, by Needle Length (2021-2033)
11.2.3. Market Revenue and Volume Forecast, by Therapy (2021-2033)
11.2.4. UK
11.2.4.1. Market Revenue and Volume Forecast, by Product (2021-2033)
11.2.4.2. Market Revenue and Volume Forecast, by Needle Length (2021-2033)
11.2.4.3. Market Revenue and Volume Forecast, by Therapy (2021-2033)
11.2.5. Germany
11.2.5.1. Market Revenue and Volume Forecast, by Product (2021-2033)
11.2.5.2. Market Revenue and Volume Forecast, by Needle Length (2021-2033)
11.2.5.3. Market Revenue and Volume Forecast, by Therapy (2021-2033)
11.2.6. France
11.2.6.1. Market Revenue and Volume Forecast, by Product (2021-2033)
11.2.6.2. Market Revenue and Volume Forecast, by Needle Length (2021-2033)
11.2.6.3. Market Revenue and Volume Forecast, by Therapy (2021-2033)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Volume Forecast, by Product (2021-2033)
11.2.7.2. Market Revenue and Volume Forecast, by Needle Length (2021-2033)
11.2.7.3. Market Revenue and Volume Forecast, by Therapy (2021-2033)
11.3. APAC
11.3.1. Market Revenue and Volume Forecast, by Product (2021-2033)
11.3.2. Market Revenue and Volume Forecast, by Needle Length (2021-2033)
11.3.3. Market Revenue and Volume Forecast, by Therapy (2021-2033)
11.3.4. India
11.3.4.1. Market Revenue and Volume Forecast, by Product (2021-2033)
11.3.4.2. Market Revenue and Volume Forecast, by Needle Length (2021-2033)
11.3.4.3. Market Revenue and Volume Forecast, by Therapy (2021-2033)
11.3.5. China
11.3.5.1. Market Revenue and Volume Forecast, by Product (2021-2033)
11.3.5.2. Market Revenue and Volume Forecast, by Needle Length (2021-2033)
11.3.5.3. Market Revenue and Volume Forecast, by Therapy (2021-2033)
11.3.6. Japan
11.3.6.1. Market Revenue and Volume Forecast, by Product (2021-2033)
11.3.6.2. Market Revenue and Volume Forecast, by Needle Length (2021-2033)
11.3.6.3. Market Revenue and Volume Forecast, by Therapy (2021-2033)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Volume Forecast, by Product (2021-2033)
11.3.7.2. Market Revenue and Volume Forecast, by Needle Length (2021-2033)
11.3.7.3. Market Revenue and Volume Forecast, by Therapy (2021-2033)
11.4. MEA
11.4.1. Market Revenue and Volume Forecast, by Product (2021-2033)
11.4.2. Market Revenue and Volume Forecast, by Needle Length (2021-2033)
11.4.3. Market Revenue and Volume Forecast, by Therapy (2021-2033)
11.4.4. GCC
11.4.4.1. Market Revenue and Volume Forecast, by Product (2021-2033)
11.4.4.2. Market Revenue and Volume Forecast, by Needle Length (2021-2033)
11.4.4.3. Market Revenue and Volume Forecast, by Therapy (2021-2033)
11.4.5. North Africa
11.4.5.1. Market Revenue and Volume Forecast, by Product (2021-2033)
11.4.5.2. Market Revenue and Volume Forecast, by Needle Length (2021-2033)
11.4.5.3. Market Revenue and Volume Forecast, by Therapy (2021-2033)
11.4.6. South Africa
11.4.6.1. Market Revenue and Volume Forecast, by Product (2021-2033)
11.4.6.2. Market Revenue and Volume Forecast, by Needle Length (2021-2033)
11.4.6.3. Market Revenue and Volume Forecast, by Therapy (2021-2033)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Volume Forecast, by Product (2021-2033)
11.4.7.2. Market Revenue and Volume Forecast, by Needle Length (2021-2033)
11.4.7.3. Market Revenue and Volume Forecast, by Therapy (2021-2033)
11.5. Latin America
11.5.1. Market Revenue and Volume Forecast, by Product (2021-2033)
11.5.2. Market Revenue and Volume Forecast, by Needle Length (2021-2033)
11.5.3. Market Revenue and Volume Forecast, by Therapy (2021-2033)
11.5.4. Brazil
11.5.4.1. Market Revenue and Volume Forecast, by Product (2021-2033)
11.5.4.2. Market Revenue and Volume Forecast, by Needle Length (2021-2033)
11.5.4.3. Market Revenue and Volume Forecast, by Therapy (2021-2033)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Volume Forecast, by Product (2021-2033)
11.5.5.2. Market Revenue and Volume Forecast, by Needle Length (2021-2033)
11.5.5.3. Market Revenue and Volume Forecast, by Therapy (2021-2033)
12.1. Becton, Dickinson and Company
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Novo Nordisk A/S
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Ypsomed AG
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Owen Mumford Ltd.
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. HTL-STREFA S.A.
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Terumo Corporation
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Allison Medical, Inc.
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Artsana S.p.A.
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Trividia Health, Inc.
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Perrigo Company plc
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
14.1. About Us
14.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample